Related Experiment Videos
Biochemical markers and bone densitometry in inflammatory bowel disease
D Ledro Cano1, Y Torres Domínguez, L Castro Laria
1Division of Gastrointestinal Diseases, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Revista Espanola De Enfermedades Digestivas
|January 4, 2001
Summary
Corticosteroid use in inflammatory bowel disease patients is linked to increased bone resorption and decreased bone mineral density. Biochemical markers did not correlate with bone densitometry in this Spanish study.
Area of Science:
- Gastroenterology
- Endocrinology
- Rheumatology
Background:
- Inflammatory bowel disease (IBD) is associated with reduced bone mineral density.
- Potential causes include delayed puberty, malabsorption, and corticosteroid use.
- Limited data exists on bone health assessment in Spanish IBD patients using biochemical markers and densitometry.
Purpose of the Study:
- To evaluate bone mineral density and biochemical markers in Spanish IBD patients.
- To investigate the relationship between corticosteroid use, bone resorption, bone formation, and bone mineral density.
Main Methods:
- 54 IBD patients (22 Crohn's disease, 32 ulcerative colitis) were studied.
- Bone mineral density was assessed using quantitative digital radiography densitometry.
- Bone resorption (urine D-pyridinoline) and formation (serum osteocalcin) markers were measured.
Main Results:
- Daily corticosteroid dose correlated positively with urine D-pyridinoline (bone resorption).
- Urine D-pyridinoline inversely correlated with serum osteocalcin (bone formation).
- Bone mineral density showed a negative correlation with corticosteroid dose.
Conclusions:
- Corticosteroid dose is directly associated with bone resorption and inversely with bone mineral density in IBD patients.
- No significant relationship was found between biochemical markers and bone densitometry.
- No differences in bone health markers were observed between Crohn's disease and ulcerative colitis.